Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now

Turnstone Biologics Corp. Prepares for Public Debut with Upsized IPO


San Diego-based biotechnology company Turnstone Biologics Corp. (TSBX) is set to go public on Friday after successfully raising $80 million in an upsized initial public offering. The company sold 6.67 million shares in the IPO, surpassing its initial projection of 5.80 million shares.

Strong Market Response

At the initial public offering price of $12 per share, Turnstone Biologics Corp. achieved a valuation of $225.86 million. The stock will be available for trading on the Nasdaq exchange under the ticker symbol “TSBX” starting Friday.

Steady Financial Performance

In the first quarter, the company reported a net income of $68,000, backed by collaboration revenue of $19.3 million. This marks a significant improvement from the previous year, which saw a loss of $12.6 million on collaboration revenue of $10.7 million.

Investor Interest in IPOs

Turnstone Biologics Corp.’s decision to go public aligns with a period of heightened investor interest in IPO shares. The Renaissance IPO exchange-traded fund (IPO) has shown a 23.6% increase over the past three months, while the S&P 500 has gained 9.7%.

Kistos Holdings Extends M10/M11 License for Five Years

Previous article

Roth 401(k) Rollover into Roth IRA

Next article

You may also like


Leave a reply

Your email address will not be published.

More in News